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The effects of nifedipine on arterial oxygenation and
hemodynamics were studied at rest and during bicycle
exercise in 12 men (mean age 55 years, range 41 to 67)
with stable exertional angina. The study was conducted
double-blind on 2 days, 1 week apart, using a placebo-
controlled crossover design. On each day, measurements
at rest were made before and 20 minutes after 20 mg
sublingual nifedipine or placebo and were followed by
measurements made during exercise. Compared with
placebo, nifedipine reduced mean arterial pressure, sys-
temic vascular resistance and pulmonary vascular re-
sistance, and increased heart rate and cardiac output at
rest and during exercise. It did not alter mean pulmo-
nary artery or pulmonary artery wedgepressures at rest,
but decreased them during exercise.
Nifedipine decreased arterial oxygen tension (Paoj)
from 96 ± 10 to 90 ± 13 min Hg (p < 0.05) at rest and
from 99 ± 11 to 92 ± 12 mm Hg (p < 0.005) at sub-
Nifedipine is used in the treatment of a wide range of car-
diovascular disorders (1-8), and is a potent dilator of sys-
temic, coronary and pulmonary arterioles (9,10). Pulmonary
vasodilators have been shown to increase ventilation-per-
fusion imbalance in the lungs and decrease arterial oxygen
tension (Pao-) (11-15). The effects of nifedipine on ven-
tilation-perfusion imbalance and Pao, have been reported
at rest in normal subjects (16) and in patients with respiratory
failure (10) and primary pulmonary hypertension (17). How-
ever, these effects have not been reported in patients with
exertional angina, either at rest or during exercise. An un-
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maximal exercise (33 ± 21 W), but did not alter it
(100 ± 12 versus 100 ± 16 mm Hg, p = NS)at maximal
exercise (68 ± 30 W). The reduction in Pao, was not
due to alveolar hypoventilation, because nifedipine did
not alter arterial carbon dioxide tension, or to changes
in mixed venous oxygen tension, which nifedipine in-
creased at rest (39 ± 2 versus 43 ± 3 mm Hg, p <
0.001) and during submaximal exercise (31 ± 4 versus
33 ± 4 mm Hg, p < 0.03) and maximal exercise (27 ±
3 versus 31 ± 3 mm Hg, p < 0.001).
These findings suggest that nifedipine reduced Pao,
at rest and submaximal exercise by increasing ventila-
tion-perfusion imbalance in the lungs, probably as a
result of pulmonary vasodilation and increase in cardiac
output. No correlation was found between the reduction
in rest Pao, and pulmonary vascular resistance, sug-
gesting that other factors were involved.
(J Am Call CardioI1986;8:1461-6)
derstanding of these actions is important, because a decrease
in arterial oxygenation may increase myocardial ischemia
in patients with coronary artery disease. This was demon-
strated in a recent study (18) in which a small reduction in
arterial oxygen saturation (Sao2) in patients with angina
increased ST segment depression during exercise.
The aims of this study were to measure the effects of 20
mg sublingual nifedipine on arterial and mixed venous blood
gases at rest and during exercise in patients with exertional
angina, and to relate these changes to systemic and pul-
monary hemodynamics.
Methods
Study patients. Twelve men (mean age 55 years, range
41 to 67) with stable exertional angina (New York Heart
Association functional class II or III) of at least 3 months'
duration were studied. All patients had a positive exercise
test (at least I mm flat or downsloping ST segment depres-
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sion at 80 ms from the J point) with the development of
typical angina . Significant coronary artery disease (~70%
diameter stenosis in at least one major coronary artery) was
documented in the eight patients who underwent cardiac
catheterization. Six patients had previous myocardial in-
farction , but none were in cardiac failure . No patient had
arterial hypertension, valvular heart disease or lung disease.
Study design. The study was approved by the Hospital
Ethics Review Committee, and informed written consent
was obtained from all patients .
Before entry into the study, all patients were familiarized
with the exercise protocol and study equipment. The study
was placebo controlled, and was conducted double-blind on
2 days, I week apart. All antianginal medications were
stopped 72 hours before each of the 2 study days, except
oral ntirates, which were stopped on the days of the study.
On each day , the patients were studied in the morning
in the fasting state without premedication. Intravascular
catheters were first inserted, and at least 30 minutes later,
control rest measurements were made . Either two to 109
nifedipine capsules or two placebo capsules were given sub-
lingually, and rest measurements were repeated after 20
minutes. Symptom-limited graded bicycle exercise was then
performed. The order of drug admini stration was random-
ized so that on the first day, half of the patients received
placebo and the other half received nifedipine. On the sec-
ond day , all patients received the alternative treatment.
Hemodynamics. A Swan-Ganz thermodilution catheter
and a radial artery cannula (17G Teflon Dwellcath) were
inserted percutaneously under local anesthesia. At rest and
exercise, measurements were made with patients seated in
a semiupright (45°) posture on a bicycle ergometer (Atomic
Products Corporation). Phasic and mean systemic arterial,
pulmonary artery, pulmonary artery wedge and right atrial
pressure s were measured using Bell and Howell 4-327-1
transducers, and recorded on an Electronics for Medicine
VR 12 recorder. The zero reference level was chosen at the
fourth intercostal space in the midaxillary line. Cardiac out-
put was measured by thermodilution using 10 ml boluses
of ice-cooled 5% dextrose in water injectate , and the values
were calculated by an Instrumentation Laboratories Com-
puter (model 701) . Systemic and pulmonary vascular re-
sistances were calculated using standard formulas (\ 9).
Rest studies. After hemodynamic measurements had
stabilized, rest measurements were made over 6 minutes.
Intravascular pressures were continuously recorded. A CMs
electrocardiographic precordial lead was continuously mon-
itored, and a 12 lead electrocardiogram was recorded every
minute . Six cardiac output measurements were made and
the values averaged. Blood (2 to 5 ml) was anaerobically
withdrawn simulataneously from the radial and pulmonary
arteries for analysis of blood gases, that is, arterial oxygen
tension (Pao-), arterial oxygen saturation (Sao-), arterial
carbon dioxide tension (Paco-), mixed venous oxygen ten-
sion (Pvo-), mixed venous oxygen saturation (Svo-) , mixed
venous carbon dioxide tension (Pvco-) and pH, using a
Corning 175 Blood Gas Analyzer.
Exercise studies. Bicycle exercise was commenced at
individually predetermined work loads based on results of
a prior exercise test , so that all patients developed angina
within 6 minutes of exercise. Work loads were controlled
by an electronically braked ergometer (Siemens-Elema) and
were increased by 15 W every 3 minutes until exercise was
stopped by symptoms . The CMs electrocardiographic lead
was continuously monitored , and a 12 lead electrocardio-
gram was recorded at I minute intervals. Intravascular pres-
sures were continuously recorded . In the last 2 minutes of
each work load level, three or four cardiac output mea-
surements were made; 2 to 5 ml of blood was simultaneously
withdrawn from the radial and pulmonary arteries at the end
of each work load level for the analysis of blood gases, as
described earlier.
Statistical analysis. The four rest measurements (two
control, postplacebo and postnifedipine) were compared us-
ing a two-way analysis of variance (20). Exercise mea-
surements between placebo and nifedipine were compared
at the same work loads using the Student's paired t test.
Two work loads were chosen : the common maximal work
load after placebo and nifedipine , and a submaximal work
load one half the maximal load. A probability (p) value of
less than 0.05 was considered statistically significant. Re-
sults are shown as mean ± I SD.
Results
Clinical response. After placebo, all patients developed
angina and ST depression during exercise. Exercise was
stopped because of angina in six patients and because of
leg fatigue in the other six. After nifedipine, the onset of
angina was abolished in four patients, delayed by at least
I minute in four patients and unaltered in the other four.
ST segment depression, compared at the common maximal
work load after placebo and nifedipine (68.0 ± 30.3 W),
was reduced from 2.5 ± 1.1 to 2.0 ± 1.0 mm (p < 0.(5).
Although nifedipine decreased angina in eight patients,
five patients reported increased leg fatigue and four of them
stopped exercise at a work load that was one level lower
after nifedipine than after placebo. As a result, nifedipine
did not alter mean exercise capacity (72.5 ± 30.6 W with
placebo, 68.8 ± 28.9 W with nifedipine; p = NS) .
Rest hemodynamics. There was no difference in hemo-
dynamic measurements between the control rest studies on
both days and between the control rest studies and the rest
study after placebo (Table 1). Nifedipine decreased systemic
vascular resistance and mean arterial pressure and increased
heart rate and cardiac output. It decreased pulmonary vas-
cular resistance, but did not alter mean pulmonary artery or
pulmonary artery wedge pressures .
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Table 1. Rest Hemodynamic Measurements in 12 Patients on Placebo and Nifedipine Days
Pre-Placebo Post-Placebo Pre-Nifedipine Post-Nifedipine
HR (beats/min) 67 ± II 67 ± II 68 ± 10 79 ± 11*
MAP (mm Hg) 123 ± 17 123 ± 16 122 ± 15 100 ± 8*
SVR (dynes-s-cm - ') 2,087 ± 409 2,065 ± 420 2,100 ± 391 1,305 ± 238*
PVR (dynes-s-cm - ') 154 ± 52 151 ± 60 153 ± 45 121 ± 48t
CO (liters/min) 4.6 ± 0.8 4.7 ± 1.0 4.6 ± 0.6 6.0 ± 0.9*
MPA (mm Hg) 17 ± 4 18 ± 4 17 ± 3 18 ± 4
PAW (mm Hg) 9 ± 3 10 ± 3 9 ± 2 10 ± 3
*p < 0.001, tp < 0.01 for post-nifedipine versus pre-nifedipine. There were no significant differences
between pre-placebo, post-placebo and pre-nifedipine values. CO = cardiac output; HR = heart rate; MAP
= mean arterial pressure: MPA = mean pulmonary artery pressure; PAW = pulmonary artery wedge pressure:
PVR = pulmonary vascular resistance: SVR = systemic vascular resistance.
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Rest blood gases. There was no difference in blood gas
measurements between the control rest studies on both days
and between the control rest studies and the rest study after
placebo (Table 2). Nifedipine decreased arterial oxygen ten-
sion (Pao-) from 96 ± 10.3 to 90 ± 13.2 mm Hg (p <
0.05). The changes in individual patients were variable (Fig.
I). Arterial oxygen saturation (Sao2) was slightly lower after
nifedipine (97.3 ± 0.8 to 96.7 ± 1.4%), but the difference
was not significant (p < 0.1). Nifedipine did not alter arterial
carbon dioxide tension (Paco-) or pH.
Nifedipine increased mixed venous oxygen tension (Pvo-)
from 39 ± 2.0 to 43 ± 2.6 mm Hg (p < 0.001) and mixed
venous oxygen saturation (SV02) from 73 ± 3.3 to 79 ±
2.5% (p < 0.001), because of the increased cardiac output.
No correlation was found (r = 0.02) between the decrease
in Pao, and the decrease in pulmonary vascular resistance
after nifedipine using a standard least squares regression
analysis.
Exercisehemodynamics. At the submaximal (33 ± 21
W) and maximal (68 ± 30 W) work loads, nifedipine de-
creased systemic and pulmonary vascular resistance, mean
arterial pressure and mean pulmonary artery and pulmonary
artery wedge pressures and increased heart rate and cardiac
output compared with placebo (Table 3).
Exercise blood gases. During exercise after placebo,
PV02 decreased progressively from 39 ± 2.7 mm Hg at rest
to 31 ± 3.8 mm Hg at submaximal exercise and 27.0 ±
2.6 mm Hg at maximal exercise (Table 4). At submaximal
exercise, nifedipine decreased Pao, from 99 ± 10.8 mm
Hg (placebo) to 92 ± 11.5 mm Hg (p < 0.01) (Fig. I) and
Sao, slightly from 97.3 ± 1.0% (placebo) to 96.8 ± 1.2%
(p < 0.05). Because of the increased cardiac output, ni-
fedipine increased PV02 from 31 ± 3.8 mm Hg (placebo)
to 33 ± 3.6 mm Hg (p < 0.05). It did not alter Paco-, but
decreased Pvco, slightly.
At maximal exercise, nifedipine did not alter Pao, or
Sao-. Associated with the increased cardiac output, it in-
creased PV02 from 27 ± 2.6 mm Hg (placebo) to 31 ±
2.5 mm Hg (p < 0.001), and SV02 from 43.6 ± 8.7%
(placebo) to 53.5 ± 7.4% (p < 0.001). Nifedipine did not
alter Paco, and slightly reduced PVC02.
Discussion
Clinical response to nifedipine. All patients in this study
had a history of classic stable angina, and developed chest
pain with positive ST depression during exercise after pla-
cebo. Nifedipine abolished or delayed the onset of angina
Table 2. Rest Blood Gas Measurements on Placebo and Nifedipine Days
Pre-Placebo Post-Placebo Prc-Nifedipine Post-Nifedipine
Arterial
PaO, (mm Hg) 96.7 ± 7.6 97.1 ± 8.6 96.2 ± 10.3 89.8 ± 13.2*
SaO, (%) 97.3 ± 0.5 97.3 ± 0.6 97.3 ± 0.8 96.7 ± l.4t
PaCO, (mm Hg) 42.3 ± 2.3 41.4 ± 2.0 41.3 ± 2.3 41.1 ± 3.4
pH 7.41 ± 0.02 7.41 ± 0.02 7.41 ± 0.02 7.42 ± 0.02
Mixed venous
PvO, (mm Hg) 39.0 ± 2.6 39.2 ± 2.7 39.4 ± 2.0 43.2 ± 2.6:j:
SvO, (%) 72.4 ± 4.1 72.9 ± 4.1 72.7 ± 3.3 78.5 ± 2.5:j:
PvCO, (mm Hg) 43.8 ± 5.5 44.5 ± 2.5 45.2 ± 2.1 43.2 ± 3.2§
pH 7.39 ± 0.02 7.39 ± 0.02 7.39 ± 0.02 7.40 ± 0.02*
*p < 0.05, tp < 0.1, :j:p < 0.001, §p < 0.01 for post-nifedipine versus pre-nifedipine. PaCO, = arterial
carbon dioxide tension; Pa02 = arterial oxygen tension; PVC02 = mixed venous carbon dioxide tension;
PvO, = mixed venous oxygen tension; SaO, = arterial oxygen saturation: Svo, = mixed venous oxygen
saturation.
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Figure 1. Changes in arterial oxygen tension (Pao-) after nifed-
ipine in the 12 individual patients at rest and during submaximal
(SUBMAX) and maximal (MAX) exercise. Comparison with pla-
cebo values (dashed line at 0 level).
in 8 of the 12 patients and significantly reduced ST depres-
sion. Exercise capacity was not increased overall because
exercise was performed in a strictly symptom-limited man-
ner. Six patients stopped exercise after placebo because of
leg fatigue even though moderately severe angina was also
present. In addition, four patients stopped exercise at I work
load level lower after nifedipine than after placebo because
of increased leg fatigue.
The decrease in angina after nifedipine occurred despite
reduced arterial oxygen tension (Pao-) at rest and submax-
imal exercise. There was no relation between the degree of
reduction in Pao, at rest or submaximal exercise and the
antianginal reponse to nifedipine.
Hemodynamic response to nifedipine. The hemody-
namic effects of nifedipine in this study agree with those
of previous reports (9,21,22). At rest and exercise, nifed-
ipine decreased systemic vascular resistance and mean ar-
terial pressure and increased heart rate and cardiac output.
These changes were due to peripheral arteriolar dilation by
nifedipine and the resulting reflex hemodynamic changes.
Nifedipine decreased pulmonary vascular resistance at rest,
but did not decrease mean pulmonary artery pressure be-
cause of the increase in cardiac output. During exercise,
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nifedipine decreased pulmonary vascular resistance and mean
pulmonary artery and wedge pressures.
Effects of nifedipine on rest blood gases. Nifedipine
significantly reduced arterial oxygen tension (Pao-) at rest.
This was not due to changes in mixed venous oxygen tension
(PV02), which was increased by the higher cardiac output.
Other possible explanations for the lower Pao2 included
alveolar hypoventilation, impaired oxygen diffusion, in-
creased ventilation-perfusion imbalance and increased in-
trapulmonary shunt flow (23). Arterial carbon dioxide ten-
sion (Paco-) is an index of alveolar ventilation, and because
it was unaltered, this suggested that alveolar hypoventilation
did not occur. Our patients did not have interstitial lung
disease and pulmonary artery wedge pressure did not change.
Therefore, nifedipine is unlikely to have affected the dif-
fusion of oxygen. These findings suggest that the reduction
in Pao2 after nifedipine was due either to increased venti-
lation-perfusion imbalance or intrapulmonary shunt flow,
or both.
Regional perfusion and ventilation in the normal lung is
not homogeneous and some ventilation-perfusion imbalance
normally occurs (24), especially in the upright posture (25).
Adaptive pulmonary vasoconstriction occurs in areas with
poorly ventilated alveoli, and so reduces this imbalance
(24). Nonselective pulmonary vasodilation by nifedipine
may increase blood flow to poorly ventilated areas, and
thereby increase venous admixture and decrease Pao-. The
reduction in Pao; after nifedipine varied considerably in
individual patients. There was no correlation between the
decrease in pulmonary vascular resistance in individual pa-
tients and the decrease in Pao., suggesting that other im-
portant factors were involved. The degree of adaptive pul-
monary vasoconstriction present before nifedipine and the
degree of increase in cardiac output after nifedipine (15)
could be other possible determinants of the reduction in
Pao, in individual patients.
Pulmonary vasodilation by a number ofdrugs, including
isoproterenol (12), aminophylline (13), nitroglycerin
(14,26,27) and nitroprusside (15), has been shown to in-
crease ventilation-perfusion imbalance and decrease Pao;
Table 3. Hemodynamic Measurements During Submaximal and Maximal Exercise After
Placebo and Nifedipine
Placebo
Submaximal
Nifedipine Placebo
Maximal
Nifedipine
HR (beats/min)
MAP (mm Hg)
SVR (dynes-s-cm -5)
PVR (dynes-s-cm - 5)
CO (liters/min)
MPA (mm Hg)
PAW (mm Hg)
98 ± 15
138 ± 15
1,271 ± 379
127 ± 67
8.8 ± 2.4
35 ± 8
22 ± 6
105 ± 13*
116 ± 12t
934 ± 253t
97 ± 37:1:
9.7 ± 2.2*
28 ± 4t
16 ± 4t
118 ± 20
148 ± 12
1,143 ± 409
135 ± 92
10.6 ± 3.7
44 ± 9
29 ± 6
128 ± 18t
123 ± I It
828 ± 243t
90 ± SIt
11.8 ± 3.4*
33 ± 9t
21 ± sr
*p < 0.01, tp < 0.001, :j:p < 0.05 for nifedipine versus placebo. Abbreviations as in Table I.
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Table 4. Blood Gas Measurements During Submaximal Exercise After Placebo and Nifedipine
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Placebo
Submaximal
Nifedipine Placebo
Maximal
Nifedipine
Arterial
Pao2 (mm Hg)
Sao2 (%)
PaC02 (mm Hg)
pH
Mixed venous
PV02 (mm Hg)
SV02 (%)
PVC02 (mm Hg)
pH
99.1 ± 10.8
97.3 ± 1.0
41.6 ± 2.4
7.40 ± 0.03
30.8 ± 3.8
53.4 ± 6.9
49.6 ± 3.3
7.36 ± 0.03
91.7 ± 11.5*
96.8 ± 1.2t
40.8 ± 2.3
7.40 ± o.m
33.1 ± 3.61'
60.2 ± 7.3:1:
48.0 ± 3.2*
7.36 ± 0.03
99.7 ± 11.8
97.5 ± 0.7
39.2 ± 2.3
7.39 ± 0.03
26.8 ± 2.6
43.6 ± 8.7
52.9 ± 3.5
7.31 ± (J.05
99.8 ± 16.4
97.3 ± l.l
39.3 ± 2.7
7.39 ± 0.03
31.1 ± 2.5:1:
53.5 ± 7.4:1:
50.3 ± 4.0t
7.32 ± 0.04
*p < 0.01. tp < 0.05. :l:p < 0.001 for nifedipine versus placebo. Abbreviations as in Table 2.
in various clinical situations. There have been few studies
of such changes after nifedipine (10,16), and its effects in
patients with angina are poorly defined. Naeige et al. (16)
reported that 20 mg of sublingual nifedipine did not alter
Pao2 in eight healthy volunteers breathing room air. A pos-
sible explanation for this difference in results is that nifed-
ipine did not alter pulmonary vascular resistance in their
study. Their volunteers were younger than our patients and
so may have had less baseline ventilation-perfusion imbal-
ance (24). Also their measurements were made in the supine
posture which may have been associated with less venti-
lation-perfusion imbalance than the upright or semiupright
posture (25).
In patients with exertional angina, Tirlapur and Mir (18)
recently reported that nadolol decreased arterial oxygen sat-
uration (Sao-), and that the addition of nifedipine but not
nitroglycerin to nadolol slightly increased Sao, to pre-na-
dolol values. However, they measured Sao; noninvasively
by earoximetry and did not study nifedipine alone. In pa-
tients with chronic obstructive lung disease and acute res-
piratory failure, on the other hand, 20 mg of sublingual
nifedipine markedly decreased pulmonary vascular resist-
ance, and decreased Pao; from 42 to 38 mm Hg (10).
Effects of nifedipine on blood gases during exercise.
The effects of nifedipine and other pulmonary vasodilators
on ventilation-perfusion imbalance during exercise have not
been well described. At submaximal exercise, nifedipine
decreased Pao-, despite increasing PV02 because of the in-
creased cardiac output. Nifedipine did not alter Paco-, sug-
gesting that alveolar ventilation did not change, and reduced
pulmonary artery wedge pressure. For the same reasons as
were discussed in relation to conditions at rest, the reduction
in Pao-, therefore, probably resulted from an increase in
ventilation-perfusion imbalance or intrapulmonary shunt flow,
or both.
At common maximal work loads, nifedipine did not alter
Pao-, although it still decreased pulmonary vascular resist-
ance and increased cardiac output. As nifedipine increased
PV02 and SV02, it could still have increased venous admix-
ture, but to a lesser extent than at submaximal work loads.
The different effects of nifedipine on Pao2 at submaximal
and maximal exercise cannot be explained from our results.
It is possible that as regional ventilation and perfusion be-
came more homogeneous during exercise (25,28,29), the
effects of pulmonary vasodilation in poorly ventilated re-
gions became less prominent.
Limitations of the study. The effects of nifedipine on
blood gases were interpreted by deduction in this study, and
the more direct measurement of ventilation-perfusion im-
balance using inert gas elimination (15) may provide ad-
ditional information about pathophysiologic mechanisms
underlying these changes both at rest and during exercise.
Results from single dose studies may not necessarily apply
to long-term oral therapy, and further investigation of these
effects during long-term nifedipine therapy is indicated.
Clinical implications. There was no obvious relation
between the decrease in Pao, at rest and submaximal ex-
ercise and the antianginal response to nifedipine. In this
study, the mean reduction in Pao, after nifedipine was rel-
atively small and the reduction in Sao-, was minimal. This
was probably because our patients did not have lung disease
and values of Pao, were in the plateau portion of the hemo-
globin-oxygen dissociation curve (30). In patients with myo-
cardial infarction who may have small airways disease (31 ,32),
and in patients with lung disease and increased ventilation-
perfusion imbalance, pulmonary vasodilation may theoret-
ically reduce Pao, more than it did in the patients in this
study. Also, in hypoxic patients who have Pao- values in
the steep portion of the hemoglobin-oxygen dissociation
curve, a similar reduction in Pao, may produce a much
larger decrease in arterial oxygen saturation and content.
Care is required when administering nifedipine to such pa-
tients.
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